| Samantha J Lewis, CRNP | |
|
777 Bannock St, Denver, CO 80204-4507 | |
| (303) 602-6196 | |
| Not Available |
| Full Name | Samantha J Lewis |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 777 Bannock St, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013429513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | F06171769 (Nebraska) | Secondary |
| 363L00000X | Nurse Practitioner | SP018545 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clearview Dermatology Pllc | 6507265121 | 5 |
News Archive
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.
Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.
"Many currently believe that U.S. domestic entitlements are too large, but disregard the fact that the PEPFAR program has created a new class of moral entitlements overseas - in the form of four million and counting people receiving U.S.-supported life-sustaining AIDS treatment in low- and middle-income countries around the world," Mead Over, a senior fellow at the CGD, writes in the Center for Global Development's (CGD) "Global Health Policy" blog.
› Verified 7 days ago
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.
Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.
"Many currently believe that U.S. domestic entitlements are too large, but disregard the fact that the PEPFAR program has created a new class of moral entitlements overseas - in the form of four million and counting people receiving U.S.-supported life-sustaining AIDS treatment in low- and middle-income countries around the world," Mead Over, a senior fellow at the CGD, writes in the Center for Global Development's (CGD) "Global Health Policy" blog.
› Verified 7 days ago
| Entity Name | Signify Health Medical Associates Of Colorado Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023625662 PECOS PAC ID: 8527474899 Enrollment ID: O20210311000251 |
News Archive
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.
Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.
"Many currently believe that U.S. domestic entitlements are too large, but disregard the fact that the PEPFAR program has created a new class of moral entitlements overseas - in the form of four million and counting people receiving U.S.-supported life-sustaining AIDS treatment in low- and middle-income countries around the world," Mead Over, a senior fellow at the CGD, writes in the Center for Global Development's (CGD) "Global Health Policy" blog.
› Verified 7 days ago
| Entity Name | Clearview Dermatology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548874449 PECOS PAC ID: 6507265121 Enrollment ID: O20210601001473 |
News Archive
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.
Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.
"Many currently believe that U.S. domestic entitlements are too large, but disregard the fact that the PEPFAR program has created a new class of moral entitlements overseas - in the form of four million and counting people receiving U.S.-supported life-sustaining AIDS treatment in low- and middle-income countries around the world," Mead Over, a senior fellow at the CGD, writes in the Center for Global Development's (CGD) "Global Health Policy" blog.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samantha J Lewis, CRNP Po Box 858, Mc A410, Hershey, PA 17033-0858 Ph: (800) 243-1455 | Samantha J Lewis, CRNP 777 Bannock St, Denver, CO 80204-4507 Ph: (303) 602-6196 |
News Archive
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure.
Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.
"Many currently believe that U.S. domestic entitlements are too large, but disregard the fact that the PEPFAR program has created a new class of moral entitlements overseas - in the form of four million and counting people receiving U.S.-supported life-sustaining AIDS treatment in low- and middle-income countries around the world," Mead Over, a senior fellow at the CGD, writes in the Center for Global Development's (CGD) "Global Health Policy" blog.
› Verified 7 days ago